Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase1b/2 Study Combining Hepatic Percutaneous Perfusion With Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma

Next Previous
Trial Profile

Phase1b/2 Study Combining Hepatic Percutaneous Perfusion With Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Melphalan (Primary) ; Nivolumab (Primary)
  • Indications Cancer metastases; Liver metastases; Uveal melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CHOPIN

Most Recent Events

  • 08 Nov 2024 Status changed from recruiting to active, no longer recruiting, According to a Delcath Systems media release.
  • 05 Aug 2024 According to a Delcath Systems media release,independent investigators at the Leiden University have enrolled 70 of the total 76 patients planned in the Phase 2 part of the CHOPIN trial.
  • 13 Nov 2023 According to a Delcath Systems media release, an interim futility analysis conducted in September resulted in the independent data monitoring committee recommending continuing the study without modification.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top